WO2023049747A1 - Compositions enzymatiques lytiques de streptococcus suis et leurs procédés d'utilisation - Google Patents

Compositions enzymatiques lytiques de streptococcus suis et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2023049747A1
WO2023049747A1 PCT/US2022/076781 US2022076781W WO2023049747A1 WO 2023049747 A1 WO2023049747 A1 WO 2023049747A1 US 2022076781 W US2022076781 W US 2022076781W WO 2023049747 A1 WO2023049747 A1 WO 2023049747A1
Authority
WO
WIPO (PCT)
Prior art keywords
plyss2
clause
veterinary composition
enzyme
combination
Prior art date
Application number
PCT/US2022/076781
Other languages
English (en)
Inventor
Yong-fu LI
Original Assignee
Elanco Us Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc. filed Critical Elanco Us Inc.
Publication of WO2023049747A1 publication Critical patent/WO2023049747A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present disclosure relates to a lytic enzyme of Streptococcus suis as well as formulations and methods utilizing the lytic enzyme for the treatment of animals.
  • Streptococcus suis (S. suis) is a Gram-positive bacterium that is known to be pathogenic in some animals.
  • a lytic enzyme derived from a Streptococcus suis phage is known as “PlySs2.”
  • PlySs2 is an enzyme that hydrolyzes the cell wall of Gram-positive bacteria, including Streptococcus suis.
  • the present disclosure provides veterinary compositions comprising a PlySs2 active compound that are adapted for administration to a non-human animal.
  • the present disclosure is directed to a veterinary composition
  • a veterinary composition comprising a PlySs2 active compound and one or more carriers, wherein the PlySs2 active compound is adapted for administration to a non-human animal.
  • the carrier can be selected from the group consisting of saline, glucose, alcohols, glycols, esters, amides, and a combination thereof.
  • the veterinary composition can be a single unit dose.
  • the veterinary composition can be a parenteral formulation administered to the non-human animal via a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular and subcutaneous.
  • a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular and subcutaneous.
  • the PlySs2 active compound can be a modified PlySs2.
  • the modified PlySs2 comprises an albumin binding domain.
  • the veterinary composition can further comprise a second active compound.
  • the present disclosure is directed to a method of treating a disease in the non-human animal.
  • the method can comprise administering the veterinary composition of the present disclosure to the animal.
  • the disease can be associated with a Gram positive bacterium.
  • the Gram positive bacterium can be a Streptococcus bacterium.
  • the non- human animal can be a swine.
  • the method of treating a disease can comprise administering an amount of PlySs2 between about 1 mg/ kg and about 10 mg/kg to the non-human animal.
  • Administering the veterinary composition to the non-human animal can be performed for about 1 day to about 13 days.
  • the present disclosure is directed to a method of making the veterinary composition comprising a PlySs2 enzyme.
  • the method of making the veterinary composition can include a step of producing a recombinant PlySs2 enzyme from recombinant expression in a bacterium to form the PlySs2 enzyme.
  • the bacterium can y be E. coli.
  • the method of making the veterinary composition can further comprise fermenting the bacterium and isolating the PlySs2 enzyme.
  • the method of making the veterinary composition can also comprise processing the bacterium in a microfluidizer and/or chromatographically purifying the PlySs2 enzyme.
  • the method of making the veterinary composition can further comprise concentrating the PlySs2 enzyme and/or removing one or more endotoxins from the PlySs2 enzyme.
  • the method of making the veterinary composition can also comprise combining the PlySs2 enzyme and the carrier.
  • the present disclosure is directed to a kit comprising a bottle comprising the veterinary composition of the present disclosure.
  • the kit can include the veterinary composition in a parenteral formulation for administration to the non-human animal via a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrasternal, intracranial, intratumoral, intramuscular, and subcutaneous.
  • the kit can be used to treat a disease in a non-human animal that is a swine.
  • the bottle included in the kit can comprise an effective amount of the veterinary composition.
  • the effective amount of the veterinary composition can comprise an amount of PlySs2 ranging from about 1 mg/kg to about 10 mg/kg.
  • the veterinary composition in the bottle can be a ready-to-use liquid composition.
  • the veterinary composition in the bottle can be a lyophilized composition.
  • the veterinary composition in the bottle can be a single unit dose.
  • the veterinary composition in the bottle can be a multi-unit dose.
  • the kit can further include further comprising a diluent.
  • the present disclosure is directed to a method of purifying the PlySs2 enzyme.
  • the method of purifying the PlySs2 enzyme can comprise the steps of fermenting the PlySs2 enzyme, flowing the fermented PlySs2 enzyme through the chromatography device, and/or removing one or more endotoxins from the PlySs2 enzyme to form the purified PlySs2 enzyme.
  • the method of purifying the PlySs2 enzyme can also comprise the step of purifying the PlySs2 enzyme to a purity level of about 85% to about 95%.
  • the method of purifying the PlySs2 enzyme can further comprise the step of administering the effective amount of the purified PlySs2 enzyme to the non-human animal.
  • the effective amount of the purified PlySs2 enzyme can range from about 1 mg/kg to about 10 mg/kg.
  • the effective amount of the purified PlySs2 enzyme can also be about 5 mg/kg.
  • the method of purifying the PlySs2 enzyme can further comprise the step of administering the effective amount of the purified PlySs2 enzyme to the non-human animal once.
  • the method of purifying the PlySs2 enzyme can further comprise the step of administering the effective amount of the purified PlySs2 enzyme to the non-human animal once a day for about 13 days.
  • a veterinary composition comprising PlySs2 and one or more carriers.
  • parenteral formulation is selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular and subcutaneous.
  • a method of making a veterinary composition comprising a PlySs2 enzyme, wherein the method comprises the step of producing a recombinant PlySs2 enzyme from recombinant expression in a bacterium to form the PlySs2 enzyme.
  • a kit comprising a bottle comprising a veterinary composition of clause 1, any other suitable clause, or any combination of suitable clauses
  • a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular, and subcutaneous.
  • a method of purifying a PlySs2 enzyme comprising a step of fermenting the PlySs2 enzyme.
  • FIG. 1 shows the domains of a PlySs2 protein and a depiction of the PlySs2 amino acid sequence
  • FIG. 2A shows a purification scheme for purifying PlySs2
  • FIG. 2B shows a blot associated with the purification scheme of FIG. 2A and identifies the purified PlySs2;
  • FIG. 3 shows a BSL2 density reduction activity;
  • FIG. 4 shows survival curves in swine after two different dosage regimens comprising PlySs2, TG03 and TG04 treatment groups;
  • FIG. 5 shows the rectal temperature of animals in the study per day for each treatment group
  • FIG. 6 shows the percentage of animals having fever in the study per day for each treatment group
  • FIG. 7A shows exposure and percent survival results for animals in the TG03 and TG04 treatment groups
  • FIG. 7B correlates the day of mortality to the last day of detectable enzyme concentration in animals in the TG03 group of FIG. 7A;
  • FIG. 8A shows the body temperature of the six animals in Pen 6, which received PlySs2 once at a dose of 5 mg/kg (group TG03);
  • FIG. 8B shows the body temperature of the six animals in Pen 10, which received PlySs2 once daily for 13 days at a dose of 5 mg/kg (group TG04);
  • FIG. 9A shows the average exposure of animals in the three different pens which received PlySs2 once at a dose of 5 mg/kg (group TG03);
  • FIG. 9B shows the average exposure of animals in the three different pens which received PlySs2 once daily for 13 days at a dose of 5 mg/kg (group TG04);
  • FIG. 10A shows the plasma concentration of PlySs2 after the animals were administered PlySs2 at a dose of 3 mg/kg.
  • FIG. 10B shows the plasma concentration of PlySs2 after the animals were administered PlySs2 at a dose of 10 mg/kg.
  • the present disclosure provides exemplary veterinary compositions comprising an active pharmaceutical agent or an active compound (e.g., PlySs2).
  • the present disclosure also provides exemplary methods of making or using the veterinary composition.
  • the veterinary composition of the present disclosure exhibits desirable properties and provide benefits for the treatment of disease in an animal (e.g., a non-human animal).
  • the veterinary composition can comprise PlySs2.
  • PlySs2 can be specific in killing harmful bacteria associated with disease in animals (e.g., bacterial disease). Use of PlySs2 for the treatment of bacterial disease can avoid traditional antibiotic treatments of animals and can be utilized as or in an “antibiotic free” treatment course.
  • PlySs2 is a protein, it is biodegradable and advantageously does not accumulate in the body of animals. PlySs2 targets complex cell wall peptidoglycan structures in bacteria and, as a result, PlySs2 can have a lower propensity to develop resistance in animals. Additionally, since PlySs2 hydrolyzes the cell wall of the targeted bacteria, a composition comprising PlySs2 is selective in action and does not inadvertently kill any good or useful bacteria.
  • the veterinary composition can include more than one active compound or active pharmaceutical agent.
  • the veterinary composition can include PlySs2 and one or more antimicrobials, such as an antibiotic.
  • lytic enzymes such as PlySs2
  • administration of the PlySs2 can produce synergy with one or more antibiotics, such as antibiotics co- administered with the PlySs2 or antibiotics that the animal is taking to treat other disease or infectious indications.
  • the veterinary composition can be adapted, utilized, or used to treat an animal.
  • the animal can be a non-human animal.
  • the non-human animal can be any animal that is not a human, such as a ruminant animal, a zoo animal, a domestic animal, a wild animal, a bovine animal, a farm animal, or a companion animal.
  • the non-human animal can be a cattle, a goat, a sheep, a giraffe, an American Bison, an European bison, a yak, a water buffalo, a deer, a camel, an alpaca, a llama, a wildebeest, an antelope, a pronghorn, a nilgai, a swine, a duck, a goose, a chicken, a laying hen, a broiler, a turkey, a quail, an ostrich, a turkey, a pig, a boar, a sow, a gilt, a piglet, a canine, a feline, a rabbit, and/or a ferret.
  • the veterinary composition can also be adapted, utilized, or used to treat a non-human animal that produces food for humans, such as a meat-producing cattle, a milk-producing cattle, a dairy cattle, and/or a chicken capable of
  • the veterinary composition can be adapted, utilized, or used to treat an animal with a disease.
  • the disease can be associated with a microbial infection caused by a fungus, a virus, and/or a bacterium.
  • the disease can be associated with a bacterial infection, such as an infection related to a Gram positive (+) bacterium.
  • the disease can also be associated with a Methicillin Resistant Staphylococcus aureus (MRS A) infection, a Vancomycin Intermediate Staphylococcus aureus (VISA) infection, a Vancomycin Resistant Staphylococcus aureus (VRSA) infection, clinical mastitis, sub-clinical mastitis, septicaemia, inflammation, polyserositis, meningitis, and/or endocarditis.
  • MRS A Methicillin Resistant Staphylococcus aureus
  • VISA Vancomycin Intermediate Staphylococcus aureus
  • VRSA Vancomycin Resistant Staphylococcus aureus
  • the veterinary composition can also be adapted, utilized, or used to treat a disease of an animal infected with Staphylococcus aureus, Staphylococcus pseudintermedius, Staphylococcus agnetis, Staphylococcus simulans, Staphylococcus epide midis, Streptococcus suis, Streptococcus equi, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus sanguinis, Streptococcus pneumonia, Streptococcus pyogenes, group B streptococcus (GBS), group G streptococci (GGS), group E streptococci (GES), Listeria, and Enterococcus faecalis.
  • the veterinary composition can result in controlling and/or eliminating about 90% or more of bacteria in the animal. In some embodiments, the veterinary composition can result in controlling or eliminating (e.g., killing) about 90% of disease in animals on a farm. For example, the veterinary composition can result in controlling or eliminating about 90% of Streptococcus suis in animals on a farm with Streptococcus suis related diseases.
  • the veterinary composition can result in controlling or eliminating about 50% to about 100% of bacteria and/or disease in an animal, including any specific or range of percentages comprised therein.
  • the veterinary composition can result in controlling or eliminating about 50% to about 70%, about 70% to about 90%, or about 90% to about 99% of Streptococcus suis in animals on a farm with Streptococcus suis related diseases.
  • the veterinary composition can result in controlling or eliminating about 50% to about 70%, about 70% to about 90%, or about 90% to about 99% of Streptococcus equi, Streptococcus uberis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus sanguinis, Streptococcus pneumoniae; MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), S. epidermidis, S. pseudintermedius, or Listeria of animals on a farm with the respective disease.
  • Streptococcus equi Streptococcus uberis
  • Streptococcus agalactiae Streptococcus pyogenes
  • Streptococcus sanguinis Streptococcus pneumoniae
  • MRSA vancomycin-resistant Staphylococcus aureus
  • S. epidermidis S. pseudintermedius
  • the veterinary composition can result in about 20% to about 90% improvement in a morbidity rate in the animals with the disease, including any specific or range of percentages comprised therein.
  • the veterinary composition can result in about 40% to about 50%, about 50% to about 60%, or about 60% to about 80% improvement in the morbidity rate in the animals with the disease.
  • the veterinary composition can result in about 20% to about 30%, about 30% to about 50%, or about 50% to about 60% improvement in the mortality rate of the animals with the disease.
  • PlySs2 comprises a catalytic domain.
  • the catalytic domain comprises a catalytic active domain (CAD) and a catalytic binding domain (CBD).
  • the catalytic active domain also referred to as an N-terminal cysteine-histidine aminopeptidase catalytic domain, provides rapid cell wall lysis via hydrolysis.
  • the catalytic binding domain also referred to as a C-terminal SH3b cell-wall binding domain, provides high affinity binding to cell wall peptidoglycans that are essential for bacterial growth. Without being bound by any theory, it is believed that the catalytic binding domain provides targeted pathogen specificity and beneficially allows for the lack of antimicrobial resistance that can be observed with traditional antibiotics.
  • a PlySs2 protein typically comprises about 245 amino acids.
  • FIG. 1 shows the catalytic domains of PlySs2 and a depiction of the PlySs2 amino acid sequence.
  • the PlySs2 is a modified or recombinant PlySs2.
  • the modified and/or recombinant PlySs2 can be synthetically prepared (e.g., manually or automatically in a laboratory) to comprise PlySs2 and an albumin binding domain (ABD).
  • one or more amino acids in PlySs2 are synthetically modified to provide sufficient contact, connection, and/or fusion of the PlySs2 with the ABD to form the modified PlySs2.
  • an ABD can be utilized to increase the half-life of the modified PlySs2 that is present in the veterinary composition.
  • the use of ABD in therapeutic compositions is described, for example, in U.S. Patent No. 10,428,120 as well as published documents US 2014/0170142, US 2020/0040099, US 2017/0114114, JP 2017137320A, JP 2016526014A, JP 6382826B2, and CA 2694139, all of which are incorporated by reference herein in their entireties.
  • PlySs2 can naturally have a half-life of about 4 hours to about 30 hours.
  • the modified PlySs2 comprising the ABD can have an increased half-life ranging from about 5 to about 7 days, including any specific or range of time comprised therein.
  • the veterinary composition can comprise the active compound or the active pharmaceutical agent (e.g., PlySs2) and a carrier.
  • the carrier can be selected from the group consisting of saline, glucose, alcohols, glycols, esters, amides, and a combination thereof.
  • the carrier can be or can comprise a solid, a liquid, and/or a gaseous compound.
  • the carrier can be or can include a salt, water, and/or saline.
  • the carrier can be or can comprise a solution, a surfactant, a lyophilized composition, a powder, a suspension, a colloid, a crystalline solution, a slurry, a spray, and/or a dispersion.
  • the veterinary composition can be in the form of a gel capsule, a chewable tablet, and/or an injectable solution.
  • the veterinary composition can be administered orally, sublingually, intravenously, intramuscularly, intranasally, intraperitoneally, and/or subcutaneously.
  • the veterinary composition can be administered in a regimen that includes a single unit dose or multi-unit dose.
  • the veterinary composition can be administered a single time using a single unit dose of the veterinary composition.
  • the veterinary composition can be administered using a multi-unit dose by providing the animal more than one injection over a time period, such as for about 1 day to about 13 days.
  • more than one injection (e.g., two injections) of the veterinary composition can be administered for a time period, such as more than 13 days (e.g., 14 days).
  • the veterinary composition can be administered by providing the animal a single treatment dose per episode of the disease.
  • the veterinary composition can comprise an effective amount of the active compound or the active pharmaceutical agent (e.g., PlySs2).
  • the effective amount of the active compound or pharmaceutical component (e.g., PlySs2) in the veterinary composition is the amount of the active compound (e.g., PlySs2) that must be administered to the animal to provide an efficacious reduction or elimination of bacteria and/or disease.
  • the effective amount of the active compound or the active pharmaceutical component (e.g., PlySs2) can range from about 0.001 mg to about 1000 mg, including any amount or range comprised therein.
  • the effective amount of the active compound or the active pharmaceutical agent can depend on the body weight of the animal.
  • the effective amount of the active compound or the active pharmaceutical agent can range from about
  • the effective amount of the active compound can range from about 1 mg/kg to about 5 mg/kg, from about 1 mg/kg to about 10 mg/kg, from about 5 mg/kg to about 10 mg/kg, from about 10 mg/kg to about 20 mg/kg, including any amount or range comprised therein.
  • the animal can be treated by administration of a single dose of the veterinary composition comprising the effective amount of the active compound or the active pharmaceutical agent (e.g., PlySs2).
  • the animal can be treated by administration of multiple doses (e.g. multi-unit dose) of the veterinary composition comprising the effective amount of the active pharmaceutical component (e.g., PlySs2).
  • the multiple doses or multi-unit doses of the veterinary composition comprising the effective amount of the active compound or the active pharmaceutical agent (e.g., PlySs2) can be given on consecutive or intermittent days.
  • the multiple doses of the veterinary composition can be administered to an animal on about 2 to about 25 consecutive days, including any specific or range of days comprised therein, such as for about 2 to about 5, about
  • the veterinary composition can be a controlled release formulation. Preparing the veterinary composition to have a controlled release formulation provides for a slower release of the PlySs2 active compound over time to the animal. Formulating the veterinary composition to have a controlled release comprises using formulations including but not limited to polymer microspheres, polymer nanospheres, hydrogels, and/or in-situ gelling polymers.
  • the controlled release formulation comprises a hydrogel.
  • the hydrogel is a temperature sensitive hydrogel.
  • the controlled release formulation comprising the hydrogel can be a liquid at temperature at or below about 37 degrees to about 42 degrees, including any temperature or range comprised therein.
  • the controlled release formulation comprising the hydrogel can be a gel at temperature greater that about 37 degrees to about 42 degrees, including any temperature or range comprised therein.
  • the hydrogel comprises one or more temperature sensitive polymers.
  • Various temperature sensitive hydrogels and polymers are known in the art. For instance, hydrogels and polymers can be utilized in which the veterinary composition is a liquid at certain temperatures and a gel or a gel-like composition at different temperatures.
  • the controlled release formulation can comprise a nonaqueous carrier.
  • the controlled release formulation can comprise an oil carrier.
  • Formulating the veterinary composition to be associated with the oil provides for a slower release of the PlySs2 over time to the animal. For instance, if the formulation in an oil is administered parenterally to the animal, the oil causes the PlySs2 to be released in a slower manner compared to other, non-oil containing parenteral formulations.
  • the oil of the controlled release formulation can comprise any type of oil, such as a plant oil, an animal oil, an essential oil, and/or any combination thereof.
  • the present disclosure further provides a kit.
  • This kit can comprise a bottle containing the veterinary composition according to the present disclosure adapted for administration to a non-human animal.
  • the veterinary composition in the bottle can be the PlySs2 active compound and one or more carriers.
  • the carrier is selected from the group consisting of saline, glucose, alcohols, glycols, esters, amides, and a combination thereof.
  • the veterinary composition in the bottle can be a parenteral formulation administered to the non- human animal via a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular and subcutaneous.
  • a route of administration selected from the group consisting of intravenous, intraarterial, intraperitoneal, intrathecal, intradermal, epidural, intracerebroventricular, intraurethral, intrastemal, intracranial, intratumoral, intramuscular and subcutaneous.
  • the veterinary composition in the bottle can further comprise a second active compound.
  • the second active compound can comprise any antimicrobial or non- antimicrobial compound, such as a fungus, a virus, and/or a bacterium.
  • the second active compound can also be a bacterium that is the same bacterium as the first active compound, such as Streptococcus suis.
  • the second active compound can also be a bacterium that is not the same bacterium as the first active compound, such as Streptococcus suis.
  • the second active compound can be a species of Streptococcus, Staphylococcus, or Listeria.
  • the veterinary composition in the bottle can be in the form of a solution or ready-to-use liquid composition.
  • the veterinary composition in the bottle can be in the form of a lyophilized powder.
  • the veterinary composition in the bottle can be a single unit dose or a multi-unit dose.
  • the bottle can comprise an effective amount of the veterinary composition.
  • the effective amount of the veterinary composition can comprise an effective amount of active compound (e.g., PlySs2) in a single unit dose.
  • the effective amount of the veterinary composition can comprise an effective amount of active compound (e.g., PlySs2) in. in a multi-unit dose.
  • the multi-unit dose of the veterinary composition in the bottle can comprise about 2 to about 5 doses, about 5 to about 10 doses, about 10 to about 30 doses, about 30 to about 50 doses, or any specific number or range of doses comprised therein.
  • the bottle can comprise more than 50 doses.
  • the effective amount of active compound (e.g., PlySs2) can be the amount calculated, experimentally determined, or computationally determined to be able to treat the non-human animal (e.g., swine).
  • the kit can include a diluent.
  • the diluent can be any non-active solute or solution that enables or enhances the administration or activity of the active compound (e.g., PlySs2) to the animal.
  • the diluent of the present disclosure can comprise saline, buffer, and/or water.
  • the kit can further include an instruction manual, which contains information and directions for proper administration and/or dosages of the veterinary composition to one or more types of animals.
  • a method of treating a disease in a non-human animal can include administering the veterinary composition to the non-human animal, the disease can be associated with a Gram positive bacterium (e.g., Streptococcus bacterium).
  • the non-human animal can be any of the animals described previously including, but not limited to a swine.
  • the method of administering the veterinary composition can include administering an amount of PlySs2 from about 1 mg/ kg to about 10 mg/kg including any amount or range comprised therein to the non-human animal.
  • the method of treating a disease in a non-human animal can comprise administering the veterinary composition to the non-human animal once.
  • the method can comprise administering the veterinary composition to the non- human animal once a day for 2 to about 13 consecutive days. In some further embodiments, the method can comprise administering the veterinary composition to the non-human animal for more than 13 days (e.g., 14 days).
  • a method of making or using a veterinary composition comprises a PlySs2 enzyme.
  • This method can include the step of producing a recombinant PlySs2 enzyme from recombinant expression in a bacterium to form the PlySs2 enzyme.
  • the bacterium can be E. coli or any other bacterium that can be utilized for the production of the recombinant PlySs2.
  • the method of producing a recombinant PlySs2 enzyme (e.g., a modified PlySs2 protein) in the bacterium can include fermenting the bacterium and/or isolating the PlySs2 enzyme.
  • the method can include processing the bacterium in a microfluidizer and purifying the PlySs2 enzyme.
  • the purifying step can comprise chromatographically purifying the PlySs2 enzyme in a chromatography device.
  • the method can include concentrating the PlySs2 enzyme and/or removing one or more endotoxins from the PlySs2 enzyme.
  • the method can also include combining the purified PlySs2 enzyme with a carrier in order to make or use the veterinary composition.
  • a method of purifying a PlySs2 enzyme comprises the steps of fermenting the PlySs2 enzyme, flowing the fermented PlySs2 enzyme through the chromatography device, and/or removing one or more endotoxins from the PlySs2 enzyme to form the purified PlySs2 enzyme.
  • the method of purifying PlySs2 can comprise purifying the PlySs2 enzyme to a purity level of about 70% to about 99%, including any percentage or range comprised therein. More specifically, the method of purifying PlySs2 can comprise purifying the PlySs2 enzyme to a purity level of about 70% to about 80, about 80% to 90%, about 90% to about 95%, or about 95% to about 99%.
  • the method of purifying PlySs2 can also include combining the purified PlySs2 enzyme with a carrier in order to make or use the veterinary composition that can be administered to any non-human animal.
  • the method can also include administering the effective amount of the purified PlySs2 enzyme to the non-human animal.
  • the method can further include administering to the non-human animal about 0.5 mg/kg to about 15 mg/kg, including any specific amount or range of enzyme comprised therein.
  • the method can include administering to the non-human animal about 5 mg/kg to about 10 mg/kg, about 10 mg/kg to about 15 mg/kg, including any amount or range of enzyme comprised therein.
  • the method can include administering about 5 mg/kg of the purified PlySs2 enzyme to the non-human animal.
  • the method can further include administering the effective amount of the purified PlySs2 enzyme to the non-human animal once.
  • the method can further include administering the effective amount of the purified PlySs2 enzyme to the non-human animal once a day for a period of consecutive days.
  • the period of consecutive days can range from 1 day to 13 days. In some embodiments, the period of consecutive days can be more than 13 days (e.g., 14 days).
  • the instant example describes an exemplary process for preparing PlySs2.
  • the expression platform for preparing PlySs2 was E. coli TOPIC, pBAD24, inducible with arabinose. Fermentation was performed on a pilot scale in 30-L fermenters. Cell processing was performed using a microfluidizer and purification was done via flow through IEX chromatography. Finally, the PlySs2 was concentrated and underwent diafiltration and endotoxin removal. A purification scheme for purifying PlySs2 is shown in FIG. 2A. A blot associated with the purification scheme is illustrated in FIG. 2B.
  • FIG. 2B illustrates 4 lanes showing total lysate, a soluble fraction of the lysate, total insoluble lysate, and a purified PlySs2.
  • FIG. 2B identifies the purified PlySs2 as a 26 kDa molecule.
  • the yield of the PlySs2 production process was 10 to 30 g (purified) PlySs2 per 30 L fermenter, with 85-95% purity by sodium dodecyl sulfate (SDS).
  • the formulation of PlySs2 was prepared to be 13 mg/ml, in 10 mM Tris-HCl (pH 7.4, 20% glycerol). Preliminary analysis indicated that activity/stability was retained at 4 °C for at least 1 month (via activity assay and visual inspection) and that activity was retained after 3 year frozen storage (via activity assay).
  • a BSL2 density reduction activity assay was performed and results are shown in FIG. 3. Briefly, S. suis was washed with buffer and diluted to ODeoo ⁇ 1.5 as substrate. PlySs2 was serially diluted to seven different targeted concentrations (40, 20, 10, 5, 2.5, 1.25, and 0.625 pg/ml). A density reduction assay (DRA) assay was performed by mixing 25 pl cells with 25 pl PlySs2 in a 96-well half area flat bottom clear plate. Then, ODeoo was read at room temperature for 1 hr with shaking between each read. The ODeoo for each of the concentrations is shown in FIG. 3.
  • DPA density reduction assay
  • the instant example evaluates the effectiveness of PlySs2 at two different dosage regimens in swine.
  • Veterinary compositions comprising PlySs2 were administered individually to swine intramuscularly (IM) in order to reduce the incidence of S. suis in a challenge model.
  • IM intramuscularly
  • the example utilized an established intranasal challenge model.
  • 2 ml of 1 % acetic acid was given to animals by intranasal (IN) application.
  • IN intranasal
  • animals were given 4 mL of a challenge of S. suis via IN application.
  • control or PlySs2 treatments were performed.
  • the live phase was 21 days long.
  • the primary variable of the instant example was mortality of the animals and secondary variables included body temperature, clinical signs, blood septicemia, lung lesions, bacteria isolation (necropsy), average daily gain (ADG), and body weight.
  • In vivo exposure of PlySs2 was evaluated via blood collection on: Day 0 (prior challenge), Day 1 (prior first treatment), Day 2, Day 3, Day 4, Day 7, Day 9, Day 11, Day 14, Day 16, and Day 21.
  • FIG. 5 shows the rectal temperature of animals in the study per day for each treatment group.
  • FIG. 6 shows the percentage of animals having fever in the study per day for each treatment group.
  • FIG. 5 shows that the animals in the groups treated with the active compound had lower temperature than the animals treated with either baytril or sterile buffer.
  • FIG. 6 shows that the percentage of animals with fever in the groups treated with the active compound was lower than the percentage of animals with fever in the groups treated with either baytril or a sterile buffer.
  • FIG. 7 A shows exposure and percent survival results for animals in the TG03 and TG04 treatment groups. About 83.3% of the treated animals were shown to survive on day 21 post treatment if they were administered the active compound for 13 consecutive days. Alternatively, if the animals were administered the active compound only once, about 11.8% of treated animals were shown to survive on day 21 post treatment.
  • FIG. 7B correlates the day of mortality to the last day of detectable enzyme concentration in animals in the TG03 group. The majority of animals did not show any detectable level of enzyme concentration more than 2 days after being administered the active compound.
  • FIGS. 8A and 8B there was no observed correlation between exposure and body temperature. Without aligning with any theory, FIG. 8A suggests that there can be influence of individual innate immunity in Subject 64.
  • FIG. 8A shows results of the 6 animals in Pen 6, which received PlySs2 once at a dose of 5 mg/kg (group TG03).
  • FIG. 8B shows results of the 6 animals in Pen 10, which received PlySs2 once daily for 13 days at a dose of 5 mg/kg (group TG04).
  • FIGS. 9A and 9B shows individual exposures to PlySs2 for various animals in the PlySs2 treatment groups. As illustrated in FIG.
  • mice in Pens 1, 6, and 9 received PlySs2 once at a dose of 5 mg/kg (group TG03). Most of these animals exhibited a declining plasma concentration of the enzyme after day 1, the only day that the animals were administered the active compound.
  • animals in Pens 3, 4, and 10 received PlySs2 once daily for 13 days at a dose of 5 mg/kg (group TG04). Most of these animals exhibited a declining plasma concentration of the enzyme after day 13, the last day that these animals were administered the active compound.
  • the instant example shows that a daily dosing schedule (i.e., once daily dosing of PlySs2) correlated with efficacy and improved survival of animals. A reduction in clinical signs was observed and animals did not have any injection site reactions.
  • the instant example evaluates pharmacokinetics of PlySs2 at different dosages.
  • Animals were administered PlySs2 at a dose of 3 mg/kg and at a dose of 10 mg/kg. There were four animals in each group.
  • the results of the pharmacokinetic study for a dose of 3 mg/kg for each animal is shown in FIG. 10A.
  • the results of the pharmacokinetic study for a dose of 10 mg/kg for each animal is shown in FIG. 10B.
  • FIGS. 10A and 10B illustrate the plasma concentration of PlySs2 over a period of time after the animals were dosed.
  • the maximum concentration of PlySs2 (Cmax) was dose responsive, but not dose proportional. Furthermore, the area under the curve of PlySs2 (AUC) did not clearly increase with increase in dose. The half-life of PlySs2 was generally around 4 hours in duration, with two subjects observed to have a half-life of greater than 30 hours.
  • embodiments “comprising,” “including,” or “having” an element or a plurality of elements having a particular property can include additional such elements not having that property.
  • the term “comprising” or “comprises” refers to a composition, compound, formulation, or method that is inclusive and does not exclude additional elements, components, and/or method steps.
  • the term “comprising” also refers to a composition, compound, formulation, or method embodiment of the present disclosure that is inclusive and does not exclude additional elements, components, or method steps.
  • the phrase “consisting of’ or “consists of’ refers to a compound, composition, formulation, or method that excludes the presence of any additional elements, components, or method steps.
  • the term “consisting of’ also refers to a compound, composition, formulation, or method of the present disclosure that excludes the presence of any additional elements, components, or method steps.
  • the phrase “consisting essentially of’ or “consists essentially of’ refers to a composition, compound, formulation, or method that is inclusive of additional elements, components, or method steps that do not materially affect the characteristic(s) of the composition, compound, formulation, or method.
  • the phrase “consisting essentially of’ also refers to a composition, compound, formulation, or method of the present disclosure that is inclusive of additional elements, components, or method steps that do not materially affect the characteristic(s) of the composition, compound, formulation, or method steps.
  • Approximating language can be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as “about,” and “substantially” is not to be limited to the precise value specified. In some instances, the approximating language can correspond to the precision of an instrument for measuring the value.
  • range limitations can be combined and/or interchanged. Such ranges are identified and include all the sub-ranges contained therein unless context or language indicates otherwise.
  • the terms “can” and “can be” indicate a possibility of an occurrence within a set of circumstances; a possession of a specified property, characteristic or function; and/or qualify another verb by expressing one or more of an ability, capability, or possibility associated with the qualified verb. Accordingly, usage of “can” and “can be” indicates that a modified term is apparently appropriate, capable, or suitable for an indicated capacity, function, or usage, while taking into account that in some circumstances, the modified term can sometimes not be appropriate, capable, or suitable. [0092] It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments (and/or aspects thereof) can be used individually, together, or in combination with each other.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions vétérinaires comprenant PlySs2, ainsi que des procédés d'utilisation, de fabrication ou de production de la composition vétérinaire contenant PlySs2, présentant des propriétés souhaitables et offrant des avantages pour le traitement d'une maladie chez des animaux.
PCT/US2022/076781 2021-09-22 2022-09-21 Compositions enzymatiques lytiques de streptococcus suis et leurs procédés d'utilisation WO2023049747A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246971P 2021-09-22 2021-09-22
US63/246,971 2021-09-22

Publications (1)

Publication Number Publication Date
WO2023049747A1 true WO2023049747A1 (fr) 2023-03-30

Family

ID=85721235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/076781 WO2023049747A1 (fr) 2021-09-22 2022-09-21 Compositions enzymatiques lytiques de streptococcus suis et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2023049747A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264830A1 (en) * 2005-09-29 2009-10-22 Infa S.A. Kit for Parenteral Administration of Medicaments
US20130337528A1 (en) * 2010-12-10 2013-12-19 Tracy Thompson Compositions for separation methods
US20150225464A1 (en) * 2012-09-25 2015-08-13 Affibody Ab Albumin binding polypeptide
US20200149025A1 (en) * 2011-04-21 2020-05-14 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US20210032294A1 (en) * 2018-02-26 2021-02-04 Contrafect Corporation MODIFIED PlySs2 LYSINS AND USES THEREOF

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264830A1 (en) * 2005-09-29 2009-10-22 Infa S.A. Kit for Parenteral Administration of Medicaments
US20130337528A1 (en) * 2010-12-10 2013-12-19 Tracy Thompson Compositions for separation methods
US20200149025A1 (en) * 2011-04-21 2020-05-14 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US20150225464A1 (en) * 2012-09-25 2015-08-13 Affibody Ab Albumin binding polypeptide
US20210032294A1 (en) * 2018-02-26 2021-02-04 Contrafect Corporation MODIFIED PlySs2 LYSINS AND USES THEREOF

Similar Documents

Publication Publication Date Title
US9662380B2 (en) C. perfringens alpha toxoid vaccine
JP4664678B2 (ja) 抗菌性組成物および使用のための方法
Byrne et al. Innate immunomodulation in food animals: evidence for trained immunity?
US20150044175A1 (en) Bacteriophage preparations and methods of use thereof
US9320795B2 (en) Bacteriophage preparations and methods of use thereof
JP6262728B2 (ja) 弱毒化ストレプトコッカス・スイスワクチン並びにその製造方法及び使用
Zhang et al. A combined Clostridium perfringens/Trueperella pyogenes inactivated vaccine induces complete immunoprotection in a mouse model
US20220257743A1 (en) Klebsiella vaccine and methods of use
Songer Enteric clostridia
WO2023049747A1 (fr) Compositions enzymatiques lytiques de streptococcus suis et leurs procédés d'utilisation
Dong et al. Efficacy of enteric‐coated tilmicosin granules in pigs artificially infected with Actinobacillus pleuropneumoniae serotype 2
Chelliappan et al. Applications of igy in veterinary medicine
Glajzner et al. Pathogenicity and drug resistance of animal streptococci responsible for human infections
Amer et al. Experimentally induction and control of cellulitis in broiler chickens
Karzis Antibiotic resistance of coagulase positive Staphylococci isolated from milk of South African dairy herds
US20230263865A1 (en) Compositions and methods comprising lysin plycp025 and derivatives thereof
CN111437249B (zh) 一种复方硫酸庆大霉素注射液及其制备方法及其用途
RU2583886C2 (ru) Мультипотентная вакцина для профилактики и лечения преимущественно инвазионных и инфекционных болезней, способ применения
Zhong et al. Brindha Chelliappan, Antonysamy Michael, Celina G. Vega
Al-Awseya et al. Efficacy and Safety of Ceftiofur for Treating Serious Respiratory Diseases in Cattle: Clinical, Histopathological, and Microbiological Assessments
CN117279934A (zh) 用于抑制猪链球菌的cath2及其衍生物
Matthews Clinical forum: bovine lungworm
Mahenthiran et al. Potential for Neutralizing Chicken Egg Yolk (Igy) Generated against Mastitis Bovine, Caused by Pseudomonas aeruginosa and Klebsiella pneumoniae
VS et al. SURVEILLANCE
Fthenakis Christos Brozos, DVM, PhDa, Vasia S. Mavrogianni, DVM, PhDb

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22873823

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE